BUZZ - Vaxcyte shares dip slightly after raising 1 billion dollars for pneumococcal vaccine development
路透社2026/10/07 11:14On October 7: Vaxcyte (PCVX.O) shares fell 0.3% in premarket trading on Wednesday to $66.50, after the company completed a $1.1 billion financing round. On Tuesday night, PCVX announced the pricing (link) of approximately 7.8 million shares of common stock and pre-funded warrants at $64 per share, raising $500 million in total; simultaneously, the company launched a public offering of $500 million of convertible senior notes with a coupon rate of 1.5%, maturing on October 15, 2032. The conversion price of the convertible notes is $89.60, representing a 40% premium over the equity offering price. On Monday, PCVX shares surged around 31% after the company announced that its pneumococcal vaccine VAX-31 met all primary endpoints in late-stage clinical trials (link), generating an immune response at least comparable to that of Pfizer’s Prevnar 20 (PFE.N) and Merck’s Capvaxive (MRK.N). On Tuesday, following the launch of the public offering (link), the stock closed down nearly 10% at $66.70. PCVX plans to use the net proceeds from this offering to fund clinical development of the VAX-31 adult and pediatric programs, including the ongoing adult Phase III clinical trial of VAX-31. Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint book-running managers for the equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore act as lead managers for the convertible notes transaction. As of Tuesday’s close, PCVX shares are up about 45% year-to-date.
October 7 - ** Vaxcyte (PCVX.O) shares fell 0.3% to $66.50 in pre-market trading on Wednesday after the company completed a $1 billion financing
** PCVX announced Tuesday evening (link) that it priced approximately 7.8 million shares of common stock and pre-funded warrants at $64 per share, raising a total of $500 million; at the same time, it launched a public offering of $500 million in convertible bonds with a coupon rate of 1.5%, which will mature on October 15, 2032
** The conversion price of the convertible bonds is $89.60, representing a 40% premium to this stock offering price
** On Monday, PCVX shares surged about 31% after the company announced that its pneumococcal vaccine VAX-31 met all primary endpoints in late-stage clinical trials (link), and produced immune responses at least comparable to Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive
** On Tuesday, after the company launched (link) the public offerings, the stock closed down nearly 10% at $66.70
** The company plans to use the net proceeds from this offering to fund clinical development of the VAX-31 adult and pediatric programs, including the ongoing VAX-31 adult Phase III clinical trial
** Jefferies, Leerink, BofA Securities, Evercore, Goldman Sachs, and Guggenheim acted as joint book-running managers for the equity offering; Jefferies, Leerink, BofA Securities, Goldman Sachs, and Evercore served as lead underwriters for the convertible bonds
** As of Tuesday's close, PCVX shares were up approximately 45% year-to-date
(To assist non-English speakers, Reuters provides its reports automatically translated into several other languages. Automated translation may contain errors or lack necessary context, and Reuters does not guarantee the accuracy of the automated text. It is provided for convenience only. Reuters does not accept any responsibility for damage or losses resulting from the use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Antofagasta’s Centinela strike adds copper supply risk
Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.
Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.
Crypto prices
More
